Skip to main content

Table 3 Factors associated with fatigue

From: PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

  Bivariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age 1.032 (0.995–1.071) 0.089
PSA 1.001 (0.999–1.003) 0.464
Testosterone 0.984 (0.956–1.012) 0.248
Hb 0.821 (0.666–1.012) 0.065
LDH 0.999 (0.996–1.003) 0.680
ALP 1.001 (0.998–1.005) 0.503
Albumin 0.404 (0.159–1.025) 0.056  
Sodium 0.889 (0.782–1.010) 0.071
Alcohol consumption 2.750 (0.793–9.542) 0.111
Regular exercise 0.550 (0.294–1.031) 0.062  
Diabetes mellitus 1.918 (0.873–4.212) 0.105
Cardiovascular disorders 4.884 (1.676–14.233) 0.004 4.7 (1.6–13.9) 0.005
Respiratory disorders 3.800 (1.113–12.969) 0.033 3.6 (1.0–12.5) 0.043
High blood pressure 1.522 (0.843–2.746) 0.163
Sleep disturbances 3.982 (0.503–31.511) 0.191
Time since diagnosis 1.054 (0.981–1.132) 0.150  
Surgical castration 0.246 (0.53–1.131) 0.072
Chemical castration 0.000 (0.000-) 1.000
Radical prostatectomy at diagnosis 0.578 (0.273–1.225) 0.153
External radiation therapy at diagnosis 1.747 (0.792–3.851) 0.167
Duration of previous LHRH therapy   0.757   
7–12 months 1.000 (0.084–11.931) 1.000
13–18 months 0.583 (0.052–6.587) 0.663
19–24 months 1.111 (0.097–12.750) 0.933
25–35 months 0.905 (0.080–10.210) 0.935
36–47 months 0.857 (0.076–9.695) 0.901
48–59 months 0.571 (0.049–6.606) 0.654
≥ 60 months 1.333 (0.131–13.586) 0.808
Urinary catheter 3.857 (0.527–28.241) 0.184
Haematuria 4.370 (0.556–34.346) 0.161
  1. CI Confidence interval, Hb Haemoglobin, LDH Lactate dehydrogenase, LHRH Luteinizing hormone-releasing hormone, OR Odds ratio, PSA Prostate-specific antigen